Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness Organogenesis recommends CMS also implement an integrated coverage and payment policy CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare & Me...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. Management will host a conference call at 5:00 p.m. Eastern Time ...
A director at Prudential bought 5,000 shares at 815p and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
Prudential’s results were broadly within our expectations with NBP growing at 11% yoy. OPAT per share and DPS were ahead of consensus estimates. Management provided an upbeat 2025 guidance with double-digit growth in NBP, OPAT per share, gross OFSG and DPS. They will announce a new capital management plan during the 1H25 results. We expect a new round of buybacks which will elevate Prudential’s yield to high single digits in 2025. Maintain BUY. Target price: HK$123.00.
KEY HIGHLIGHTS Results AAC Technologies (2018 HK/BUY/HK$52.05/Target: HK$57.70) AAC’s 2H24’s earnings grew 114% yoy which exceeded expectations, thanks to a solid beat in the precision mechanics business, although this was partially offset by weaker margins from the optics and MEMs businesses. Nevertheless, we continue to expect solid revenue growth and margin expansion in 2025, driven by increasing exposure from the automotive acoustics business and edge AI-related components. Upgrade to BUY ...
GREATER CHINA Results AAC Technologies (2018 HK/BUY/HK$52.05/Target: HK$57.70): 2H24: Revenue and earnings beat; expect growth from auto and edge AI themes. Upgrade to BUY. Crystal International (2232 HK/BUY/HK$5.36/Target: HK$6.18): 2024: Record-high dividend payout; long-term wallet share gains intact. Geely Auto (175 HK/BUY/HK$18.24/Target: HK$29.00): 2024: Core earnings up 50% yoy, beating estimates. Maintain BUY. PDD Holdings (PDD US/BUY/US$125.92/Target: US$140.00): 4Q24: Earnings largely ...
A director at FTAI Aviation Ltd bought 2,200 shares at 128.790USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024. Fourth Quarter 2024 Financial Results Summary: Net revenue of $126.7 million for the fourth quarter of 2024...
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025 CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th. Management will host a conference call at 5:00 p.m....
Growth Leading This EOY Rally; Expect More Upside Our outlook remains bullish and we see the market in the midst of a significant end-of-year rally that we have been expecting since mid-October. We continue to expect support at the 20-day MAs on the S&P 500 and Nasdaq 100 (QQQ), while support at current levels or the 50-day MA is likely on the Russell 2000 (IWM). Ultimately, we will remain bullish as long as the S&P 500 is above 5850. Market dynamics continue to improve, giving us confidence th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.